ClinicalTrials.gg
CompletedNCT05357989Updated Mar 3, 2025Results posted

A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

A Phase 3 interventional study of buntanetap/posiphen and Placebo in Parkinson's Disease, Idiopathic, sponsored by Annovis Bio Inc.. Completed at 69 sites in 6 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-03-03.

Sponsored by Annovis Bio Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
523
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 386 under way, 7 of them phase 3. Parkinson Disease · United States.

Enrollment
50th of 1,256
523 · median 36
Started
2022
with 104 others
Phase 3
126 of 1,649
2 open now
Registered
1,252nd of 1,649
by date

Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 50th largest by enrollment of the 1,256 interventional ones that give a count, is one of 105 that started in 2022, is one of 126 in phase 3, and was the 1,252nd registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

299 more — sign in →

All 304 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,649 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to measure safety and efficacy of buntanetap/posiphen capsules compared with placebo capsules in participants with early PD.

Study details include:

  • The study duration will be up to 7-8 months.
  • The double-blind treatment duration will be up to 6 months.
  • There will be 5 in-clinic visits and 7 phone calls
Read the detailed description

450 early Parkinson's Disease (PD) patients will be randomized to 10mg, 20 mg of buntanetap/posiphen or placebo. They will undergo a Screening Visit, and if they provide informed consent and are considered eligible per the inclusion and exclusion criteria, will proceed to participate in the treatment period. Randomized participants will visit the clinic for the first-time dosing in clinic with administration of 10 mg or 20mg of buntanetap/posiphen or placebo, followed by an at home dosing period of 6 months, with daily administration of 10 mg or 20mg of buntanetap/posiphen or Placebo. Participants will be required to visit clinics 1 month, 2 months, 3 months, and 6 months (end-of-trial), where they will undergo study procedures that include safety assessments (AE and concomitant medication monitoring, 12-lead ECGs, clinical laboratory testing, vital signs assessments, and physical examinations) and psychometric tests (MDS-United Parkinson's Disease Rating Scale (MDS-UPDRS), Clinical Global Impression of Severity (CGIS), Wechsler Adult Intelligence Scales (WAIS), Mini-Mental State Examination (MMSE)) and Participant Global Impression of Change (PGIC). At the end of blood sampling, the subjects will need to stay for a minimum of 1 hour of observation. After all end-of-study procedures are complete, the subject will be discharged to home. A 24-hour follow-up call will occur after all clinical visits to assess the participants current condition and if there are any additional adverse events to report.

Buntanetap/posiphen has shown to improve PD subjects' mobility. MDS-UPDRS sum of score of Part II + Part III and Total score of all four parts will be measured to assess its improvement on PD subjects daily living, mobility and complications. PGIC will also be measured to assess its effect.

Buntanetap/posiphen has shown to reduce inflammation and preserve axonal integrity and synaptic functions as well as neurotoxic proteins in previous Phase 2a studies. In this study we plan to measure plasma glial fibrillary acidic protein (GFAP), neurofilament light (NFL) and potentially TDP43.

Reports of adverse events (AEs) and serious adverse events (SAEs) during exposure to buntanetap/posiphen will be collected to evaluate if there are any significant clinical safety issues for the study population. Extensive clinical and laboratory safety data already exist for buntanetap/posiphen; therefore, these safety measures will be sufficient in the proposed study.

For clinical, functional, and cognitive assessment measures, The subjects will be administered the Hoehn \& Yahr and the MMSE for determination of inclusion into the study. The MDS-UPDRS and PGIC will be administered for subjects' movement and daily function. The Coding subtest from the WAIS 4th edition will serve as a sensitive measure of Central Nervous System (CNS) dysfunction. MMSE will also be measured to assess subjects' cognitive change.

03

Conditions studied

  • Parkinson's Disease, Idiopathic

Browse trials for

Keywords

  • Parkinson's
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of idiopathic Parkinson Disease according to MDS Clinical Diagnostic Criteria for Parkinson's Disease.
  2. H\&Y score =1, 2 or 3 during ON-state \& OFF-state \<2hrs per day.
  3. Male or female aged 40 - 85 years.
  4. score between the range of 22-30 during screening visit (ON-state) and subjects can live independently without a caregiver.
  5. Female subjects of * must have a negative serum or urine pregnancy test at Screening, must be non-lactating and must agree to use a highly effective method of (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for 4 weeks after the last dose of trial treatment, such as:

    • Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation
    • Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation
    • Intrauterine device (IUD)
    • Intrauterine hormone-releasing system (IUS)
    • Bilateral tubal occlusion
    • Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant, and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used)
    • Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant) *Non-childbearing potential includes surgically sterilized or with no menstrual bleeding for at least one year prior to study start.
  6. Male subjects must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male subject must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

    • Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation
    • Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation
    • Intrauterine device (IUD)
    • Intrauterine hormone-releasing system (IUS)
    • Bilateral tubal occlusion 6. Female participants will be given a urine pregnancy test at the screening visit for which they should test negative.
  7. General cognition and functional performance sufficiently preserved that the subject can provide written .
  8. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the Columbia Suicide Severity Rating Scale.
  9. Stability of permitted medications prior to screening for at least 4 weeks.
  10. At screening subjects do not need to but may be on the following medication:

    • Standard of Care anti-parkinsonian medication
    • Anticonvulsant medications used for epilepsy or mood stabilization, neuropathic pain indications
    • Mood-stabilizing psychotropic agents, including, but not limited to, lithium.
  11. Adequate visual and hearing ability (physical ability to perform all the study assessments).
  12. Good general health with no disease expected to interfere with the study.
  13. Subjects previously exposed to buntanetap can still be included in the study after a 28- day wash out period.

Exclusion criteria

Exclusion Criteria:

  1. Has a history of a psychiatric disorder such as schizophrenia, bipolar disorder or major depression according to the criteria of the most current version of the (DSM). Mild depression or history of depression that is stable on treatment with a selective serotonin reuptake inhibitor (SSRI) or selective norepinephrine reuptake inhibitor (SNRI) medication at a stable dose is acceptable.
  2. History of a seizure disorder, if stable on medication is acceptable.
  3. Has a history or current evidence of long syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 475ms, or torsades de pointes.
  4. Has bradycardia (\<50 bpm) or tachycardia (>100 bpm) on the at screening.
  5. Has uncontrolled Type-1 or Type-2 diabetes. A subject with levels up to 7.5% can be enrolled if the investigator believes the subject's diabetes is under control.
  6. Has renal or hepatic impairment.
  7. Has any clinically significant abnormal laboratory values. Subjects with liver function tests ( [AST] or alanine aminotransferase [ALT]) greater than twice the will be excluded.
  8. Is at imminent risk of self-harm, based on clinical interview and responses on the C SSRS, or of harm to others in the opinion of the Investigators. Subjects must be excluded if they report suicidal ideation with intent, with or without a plan or method (e. g. positive response to Items 4 or 5 in assessment of suicidal ideation on the C SSRS) in the past 2 months, or suicidal behavior in the past 6 months.
  9. Has cancer or has had a malignant tumor within the past year, except subjects who underwent potentially curative therapy with no evidence of recurrence. (Subjects with stable untreated prostate cancer or skin cancers are not excluded).
  10. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version DSM.
  11. Participation in another clinical trial with an agent and have taken at least one dose of study medication, unless unblinded on placebo, within 60 days prior to the start of screening. The end of a previous investigational trial is the date the last dose of an investigational agent was taken, or five half-lives of the investigational drug, whichever is greater.
  12. Subjects with learning disability or developmental delay.
  13. Subjects whom the site PI deems to be otherwise ineligible.
  14. Subjects with a known allergy to the investigational drug or any of its components.
  15. Subject is currently pregnant, breast-feeding and/or lactating.
  16. Subject is currently taking inhibitors and/or inducers.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
523 participants (actual)

Study arms

  • Experimental
    10 mg buntanetap/posiphen

    Buntanetap/posiphen 10 mg oral capsule with daily administration for a period of 6 months

    Drug: buntanetap/posiphen

  • Experimental
    20 mg buntanetap/posiphen

    Buntanetap/posiphen 20 mg oral capsule with daily administration for a period of 6 months

    Drug: buntanetap/posiphen

  • Placebo comparator
    Placebo

    Placebo oral capsule with daily administration for a period of 6 months

    Drug: Placebo

Interventions

  • Drugbuntanetap/posiphen

    Drug page: Buntanetap

    HPMC (vegetarian source) capsule shells

    Also known as: Posiphen Tartrate, ANVS401

  • DrugPlacebo

    HPMC (vegetarian source) capsule shells

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Month 6 in MDS-UPDRS Part II (OFF-state)

    Change in the Score from the MDS- Unified Parkinson's Disease Rating Scale (UPDRS) Parts II from Baseline to the End of Trial. MDS-UPDRS Part II (Motor experiences of daily living) has 13 items and the score ranges from 0-52, with higher scores reflecting greater severity.

    Time frame: Baseline and 6 months visits

Secondary outcomes

  1. Change From Baseline to Month 6 in the MDS-UPDRS Part III (OFF-state)

    MDS-UPDRS Part III (motor examination) has 18 items and ranges from 0-132, with higher scores reflecting greater severity.

    Time frame: Baseline and 6 months visits

Other outcomes

  1. Change From Baseline to Month 6 in MMSE (OFF-state)

    Change in the MMSE score from Baseline to the End of Trial. MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures). Total score ranges from 0 to 30 with a lower score indicating greater disease severity.

    Time frame: Baseline and 6 months visits

07

Results

Posted Mar 3, 2025

Participant flow

Participant flow — Overall Study
MilestonePlacebo10 mg Buntanetap/Posiphen20 mg Buntanetap/Posiphen
Started176174173
Completed162159150
Not completed141523

Outcome measures

PrimaryChange From Baseline to Month 6 in MDS-UPDRS Part II (OFF-state)

Change in the Score from the MDS- Unified Parkinson's Disease Rating Scale (UPDRS) Parts II from Baseline to the End of Trial. MDS-UPDRS Part II (Motor experiences of daily living) has 13 items and the score ranges from 0-52, with higher scores reflecting greater severity.

Time frame:
Baseline and 6 months visits
Reported as:
Least squares mean · units on a scale
Change From Baseline to Month 6 in MDS-UPDRS Part II (OFF-state)
units on a scalePlacebo10 mg Buntanetap/Posiphen20 mg Buntanetap/Posiphen
Change From Baseline to Month 6 in MDS-UPDRS Part II (OFF-state)-0.10 ± 0.3110.57 ± 0.312-0.04 ± 0.319
SecondaryChange From Baseline to Month 6 in the MDS-UPDRS Part III (OFF-state)

MDS-UPDRS Part III (motor examination) has 18 items and ranges from 0-132, with higher scores reflecting greater severity.

Time frame:
Baseline and 6 months visits
Reported as:
Least squares mean · units on a scale
Change From Baseline to Month 6 in the MDS-UPDRS Part III (OFF-state)
units on a scalePlacebo10 mg Buntanetap/Posiphen20 mg Buntanetap/Posiphen
Change From Baseline to Month 6 in the MDS-UPDRS Part III (OFF-state)-2.90 ± 0.698-1.04 ± 0.697-2.66 ± 0.713
Other pre-specifiedChange From Baseline to Month 6 in MMSE (OFF-state)

Change in the MMSE score from Baseline to the End of Trial. MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures). Total score ranges from 0 to 30 with a lower score indicating greater disease severity.

Time frame:
Baseline and 6 months visits
Reported as:
Least squares mean · units on a scale
Change From Baseline to Month 6 in MMSE (OFF-state)
units on a scalePlacebo10 mg Buntanetap/Posiphen20 mg Buntanetap/Posiphen
Change From Baseline to Month 6 in MMSE (OFF-state)-0.39 ± 0.123-0.08 ± 0.123-0.05 ± 0.126
Post-hocChange From Baseline to Month 6 in MMSE (OFF-state) for Participants With Baseline MMSE Scores 20-28

Change in the MMSE score from Baseline to the End of Trial. MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures). Total score ranges from 0 to 30 with a lower score indicating greater disease severity.

Time frame:
Baseline and 6 months visits
Reported as:
Least squares mean · units on a scale
Change From Baseline to Month 6 in MMSE (OFF-state) for Participants With Baseline MMSE Scores 20-28
units on a scalePlacebo10 mg Buntanetap/Posiphen20 mg Buntanetap/Posiphen
Change From Baseline to Month 6 in MMSE (OFF-state) for Participants With Baseline MMSE Scores 20-28-0.50 ± 0.3170.65 ± 0.3130.45 ± 0.301

Adverse events

Collected over From consent to end of trial (up to 8 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/176 (0%)5/176 (2.8%)20/176 (11.4%)
10 mg Buntanetap/Posiphen1/174 (0.6%)4/174 (2.3%)15/174 (8.6%)
20 mg Buntanetap/Posiphen0/173 (0%)11/173 (6.4%)24/173 (13.9%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventPlacebo10 mg Buntanetap/Posiphen20 mg Buntanetap/Posiphen
Myocardial InfarctionCardiac disorders0/1762/1740/173
Angina PectorisCardiac disorders0/1760/1741/173
Myocardial IschaemiaCardiac disorders0/1760/1741/173
Accidental OverdoseInjury, poisoning and procedural complications0/1760/1741/173
ContusionInjury, poisoning and procedural complications0/1760/1741/173
Hip FractureInjury, poisoning and procedural complications0/1760/1741/173
GastroenteritisInfections and infestations0/1760/1741/173
Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1760/1741/173
CholangiocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1760/1741/173
Toxic EncephalopathyNervous system disorders0/1760/1741/173
Most frequent other events
Most frequent other events
EventPlacebo10 mg Buntanetap/Posiphen20 mg Buntanetap/Posiphen
NauseaGastrointestinal disorders5/1765/17411/173
Covid-19Infections and infestations10/1765/1744/173
FatigueGeneral disorders5/1765/1749/173

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo10 mg Buntanetap/Posiphen20 mg Buntanetap/PosiphenTotal
Mean65.4 ± 8.8865.0 ± 8.8565.4 ± 10.0965.2 ± 9.27
Sex: Female, Male
Sex: Female, Male(Participants)Placebo10 mg Buntanetap/Posiphen20 mg Buntanetap/PosiphenTotal
Female655455174
Male111120118349
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo10 mg Buntanetap/Posiphen20 mg Buntanetap/PosiphenTotal
Hispanic or Latino30213182
Not Hispanic or Latino146152141439
Unknown or Not Reported0112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo10 mg Buntanetap/Posiphen20 mg Buntanetap/PosiphenTotal
American Indian or Alaska Native0011
Asian44311
Native Hawaiian or Other Pacific Islander0000
Black or African American46313
White167163166496
More than one race0101
Unknown or Not Reported1001
Mini-Mental State Examination (MMSE)
Mini-Mental State Examination (MMSE)(units on a scale)Placebo10 mg Buntanetap/Posiphen20 mg Buntanetap/PosiphenTotal
Mean28.7 ± 1.7128.7 ± 1.7028.3 ± 2.1228.6 ± 1.86
08

Study locations

69 sites
  • University of Alabama at Birmingham (UAB)- The Kirklin Clinic
    Birmingham, Alabama 35233-2110, United States
  • Banner Sun Health Research Institute - Cleo Roberts Center for Clinical Research
    Sun City, Arizona 85351-3020, United States
  • Parkinson's & Movement Disorder Institue (PMDI) - Orange County Office
    Fountain Valley, California 92708, United States
  • UCSF Medical Center - Parkinson's Disease and Movement Disorders Clinic
    San Francisco, California 94143-2202, United States
  • Rocky Mountain Movement Disorder Center
    Englewood, Colorado 80113, United States
  • Ki Health Partners LLC D/B/A New England Institute for Clinical Research
    Stamford, Connecticut 06824, United States
  • Visionary Investigators Network
    Aventura, Florida 33180, United States
  • Parkinson's Disease and Movement Disorders Center of Boca Raton
    Boca Raton, Florida 33486-2359, United States
  • The Neurology Institute - Coral Springs
    Coral Springs, Florida 33067-4640, United States
  • Arrow Clinical trial
    Daytona Beach, Florida 32114, United States
  • Accel Research Sites - DeLand Clinical Research Unit
    DeLand, Florida 32720, United States
  • Coral Clinic Reserach LLC
    Homestead, Florida 33032, United States
  • Homestead Associates in Research, Inc
    Miami, Florida 33032, United States
  • Visionary Investigators Networks
    Miami, Florida 33133, United States
  • Medical Professional Clinical Research Center, INC
    Miami, Florida 33165, United States
  • Reliant Medical Research
    Miami, Florida 33165, United States
  • Ezy Medical Research Co.
    Miami, Florida 33175, United States
  • Visionary Investigators Network
    Miami, Florida 33176, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Visionary Investigators Network
    Pembroke Pines, Florida 33026, United States
  • Parkinsons Disease Treatment Center
    Port Charlotte, Florida 33952-6705, United States
  • University of South Florida (USF) - University of South Florida College of Medicine- Parkinson's Disease and Movement Disorders Center
    Tampa, Florida 33613-4808, United States
  • ClinCloud, LLC
    Viera, Florida 32940, United States
  • Conquest Research, LLC
    Winter Park, Florida 32789, United States
  • CenExel iResearch, LLC
    Decatur, Georgia 30030, United States
  • Hawaii Pacific Neuroscience, LLC
    Honolulu, Hawaii 96817, United States
  • Josephson Wallack Munshower Neurology, P.C.
    Indianapolis, Indiana 46256, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Michigan State University (MSU)- Health Team- Neurology and Ophthalmology Clinic
    East Lansing, Michigan 48824-7037, United States
  • Quest Research Institue
    Farmington Hills, Michigan 48334, United States
  • Parkinson's Disease and Movement Disorders Center of Long Island
    Commack, New York 11725-3400, United States
  • Mount Sinai West (Mount Sinai Roosevelt)
    New York, New York 10019-1147, United States
  • Ohio State University Wexner Medical Center (OSUWMC) - CarePoint Gahanna
    Columbus, Ohio 43211, United States
  • The Movement Disorder Clinic (MDC) of Oklahoma
    Tulsa, Oklahoma 74136-6372, United States
  • Abington Neurology
    Abington, Pennsylvania 19001, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19107, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Medical University of South Carolina (MUSC) - The Murray Center for Research on Parkinson's Disease and Related Disorders
    Charleston, South Carolina 29401-1189, United States
  • Veracity Neuroscience, LLC
    Memphis, Tennessee 38157, United States
  • Central Texas Neurology Consultants
    Round Rock, Texas 78681, United States
  • University of Virginia Health System (UVAHS)- Adult Neurology Clinic
    Charlottesville, Virginia 22903, United States
  • Inland Northwest Research
    Spokane, Washington 99202-1342, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Curiositas-ad-sanum GmbH
    Haag, Bavaria 83527, Germany
  • Kliniken Beelitz GmbH - Neurologisches Frachkrankenhaus fur Bewegungsstoerungen / Parkinson
    Beelitz, Brandenburg 14547, Germany
  • Paracelsus-Kliniken Deutschland GmbH & Co. KGaA - Paracelsus-Elena-Klinik Kassel
    Kassel, Hesse 34128, Germany
  • University Hospital Muenster
    Muenster, North Rhine-Westphalia 48149, Germany
  • Klinik und Poliklinik fur Neurologie - Universitatsklinikum Carl Gustav Carus an der Techischen Universitat
    Dresden, Saxony 01307, Germany
  • Neurologie Berlin - Gemeinschaftspraxis Dr. Ehret / Dr. von Pannwitz
    Berlin, 12163, Germany
  • Alexianer St. Joseph-Krankenhaus Berlin-Weissensee
    Berlin, 13088, Germany
  • Debreceni Egyetem Klinikai Központ Neurológiai Klinika (Kenézy Gyula Campus, Neurológiai Osztály)
    Debrecen, H-4032, Hungary
  • PTE AOK Neurologiai Klinika
    Pecs, H-7623, Hungary
  • Universita degli Studi di Salerno - Centro per le Malattie Neurodegenerative
    Baronissi, Campania 84081, Italy
  • San Raffaele Cassino - Centro di Cura e Prevenzione per il Parkinson
    Cassino, Lazio 3043, Italy
  • San Raffaele Pisana - Centro per la Cura e la Diagnosi del Parkinson
    Rome, Lazio 163, Italy
  • Krakowska Akademia Neurologil Sp. z o.o. - Centrum Neurologii Klinicznej
    Krakow, Malopolskie 31-505, Poland
  • Pratia MCM Krakow
    Kraków, Malopolskie 30-727, Poland
  • Unicardia Specjalstyczne Centrum Leczenia Chorob Serca I Naczyn&Unimedica Specjalistyczne Centrum Medyczne
    Kraków, Malopolskie 31-271, Poland
  • RCMed Oddzial Sochaczew
    Sochaczew, Mazowieckie 96-500, Poland
  • MTZ Clinical Research Powered by Pratia
    Warsaw, Mazowieckie 02-172, Poland
  • Specjalistyczna Praktyka Lekarska Dr. Stanislaw Ochudlo
    Katowice, Silesia 40-097, Poland
  • NEURO-CARE Sp. z o.o. Sp. Komandytowa
    Siemianowice Śląskie, Silesia 41-100, Poland
  • Hospital General Universitario de Elche
    Elche, Alicante 03203, Spain
  • Hospital Universitaris General de Catalunya (HGC)
    Sant Cugat Del Vallès, Barcelona 8195, Spain
  • Policlinica Gipuzkoa - Centro de Invesigacion Parkinson (CIP)
    Donostia-San Sebastian, Gipuzkoa 20014, Spain
  • Universidad Complutense de Madrid (UCM) - Hospital Universitario Infanta Sofia
    San Sebastián De Los Reyes, Madrid 28701, Spain
  • Universidad de Navarra - Clnica Universidad de Navarra (CUN) - Pamplona
    Pamplona, Navarra 31008, Spain
  • Universidad de Navarra - Clinica Universidad de Navarra (CUN) - Madrid
    Madrid, 28027, Spain
  • Hospital Universitario Virgen del Rocio (URVR - Instituto de Biomedicina de Sevilla (IBIS)
    Sevilla, 41015, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Dec 2023, 16 months.

Results were first posted in Mar 2025, 1 year 2 months after primary completion.

Of 39 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 16 months is below that.

Counting every sponsor, half of 67 studies reached it within 35 months; a quarter within 22 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2022
First posted
May 3, 2022
StartActual
Aug 3, 2022
Primary completionActual
Dec 4, 2023
CompletionActual
Dec 4, 2023
Results first posted
Mar 3, 2025
Last update
Mar 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05357989
Lead sponsor
Annovis Bio Inc.
Collaborators
TFS Trial Form Support
Responsible party
Sponsor
First posted
May 3, 2022
Start date
Aug 3, 2022
Primary completion
Dec 4, 2023
Completion
Dec 4, 2023
Results posted
Mar 3, 2025
Last update
Mar 3, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Buntanetap

Start the discussion